The BRAF inhibitor Zelboraf vemurafenib from Daiichi Sankyo Co. Ltd. and Roche produces about an
80% response rate in its approved indication of BRAF-mutant melanoma but only
about a 5% rate in colorectal tumors with the same mutation. Now, European and
U.S. teams have independently pinpointed epidermal growth factor receptor as the
likely missing link in these colorectal cancers, suggesting treatments combining
inhibitors of both targets could be more effective than monotherapy.1,2
Both groups are independently planning clinical trials with such combinations.
T. SciBX 5(6);
Published online Feb. 9, 2012
1. Prahallad, A. et al. Nature; published online Jan. 26, 2012;
Contact: René Bernards, The Netherlands Cancer Institute,
Amsterdam, the Netherlands
2. Corcoran, R.B. et al. Cancer Discov.; published online Jan. 16, 2012;
Contact: Jeffrey A. Engelman, Massachusetts General Hospital
Cancer Center, Boston, Mass.
3. Di Nicolantonio, F. et al. J. Clin.
Oncol. 26, 5705-5712
4. Karapetis, C.S. et al. N. Engl. J.
Med. 359, 1757-1765
5. Amado, R.G. et al. J. Clin.
Oncol. 26, 1626-1634
AND INSTITUTIONS MENTIONED
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Catalan Institute of Oncology, L'Hospitalet-Barcelona, Spain
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif.
Genentech Inc., South San Francisco, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Harvard Medical School, Boston, Mass.
Italian Foundation for Cancer Research Institute of
Massachusetts General Hospital, Boston, Mass.
Massachusetts General Hospital Cancer Center, Boston, Mass.
Merck KGaA (Xetra:MRK), Darmstadt, Germany
The Netherlands Cancer Institute, Amsterdam, the Netherlands
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Tufts Medical Center, Boston, Mass.
University of Torino, Torino, Italy